BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24851363)

  • 1. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
    Pariente A
    Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
    [No Abstract]   [Full Text] [Related]  

  • 2. HBV reactivation in immunosuppressed patients: prevention or containment?
    Ludwig E
    Hepatology; 2014 Jun; 59(6):2062-4. PubMed ID: 24753022
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
    Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
    Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy.
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    Hepatology; 2014 Aug; 60(2):765-6. PubMed ID: 24347499
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply: To PMID 24002804.
    Hsu C; Chen PJ; Cheng AL
    Hepatology; 2014 Aug; 60(2):766-7. PubMed ID: 24310720
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.
    Hay AE; Meyer RM
    J Clin Oncol; 2012 Sep; 30(26):3155-7. PubMed ID: 22891267
    [No Abstract]   [Full Text] [Related]  

  • 13. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
    Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
    Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
    Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
    J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
    Tadmor T; McLaughlin P; Polliack A
    Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
    [No Abstract]   [Full Text] [Related]  

  • 17. Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.
    Konishi T; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y
    Hematol Oncol; 2019 Aug; 37(3):303-307. PubMed ID: 30933366
    [No Abstract]   [Full Text] [Related]  

  • 18. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 20. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
    Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
    Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.